Q2 2025 saw continued EBITDA profitability and improved net loss, despite a 14% revenue decline due to delayed BD market launches and currency effects. Hydrocyn Aqua drove strong wound management growth, and early feasibility work in cardiology was initiated.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.